Postprocedural drop in hematocrit versus contrast-induced nephropathy: Eggs or chickens?  by Lai, Ming-Yu et al.
Letters to the Editor 1371
did the total group of 71 diabetic patients have a lower
red blood cell deformability when compared to controls.
Extaerythrocytic factors, such as leukocytes, plasma fib-
rinogen, and platelet microaggregates may influence fil-
tration results. I suppose the filtration technique of Brown
et al was corrected for this. These results may suggest that
the filtration pore size of 3 micrometers used by Brown et
al was more sensitive than the 5 micrometer pores filtra-
tion technique and ektacytometry that was used by us and
that the lack of difference in our patient groups reflects
this lack of sensitivity. On the other hand, the question
arises whether such subtle differences in red blood cell
deformability, if present, contribute to nephropathy in
diabetic patients.
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Reply from the Authors
We wish to thank Dr. Schut for their interest in our
study [1], and would like to reply to the issues raised in
their letter to the Editor.
We think that the results of our study do not agree with
those reported in their article published in 1993 [2] for
reasons stated in their letter. For example, we removed
leukocytes and platelets before measuring RBC deforma-
bility (RBC-df), and we opted to use the more sensitive
3 micron pore filter instead of a 5 micron pore filter.
To address the question of whether changes in RBC-
df contributes to diabetic nephropathy, we do not know
whether impaired RBC-df is a cause or consequence of
diabetic nephropathy.
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Postprocedural drop in
hematocrit versus
contrast-induced nephropathy:
Eggs or chickens?
To the Editor: In a recent issue of Kidney International,
Nikolsky et al suggested that low hematocrit (Hct) pre-
dicts contrast-induced nephropathy (CIN) after percuta-
neous coronary interventions (PCI) [1]. One impressive
finding in this study was that the postprocedural drop
in Hct (Hct = baseline Hct − postprocedural nadir
Hct) was highly correlated with CIN. However, we won-
der whether Hct resulted in CIN or, on the contrary,
it was attributed to CIN. Assuming that there was no
significant postprocedural change of body weight (BW)
or fluid status in the patients receiving PCI, Hct might
exactly reflect acute blood loss. The most possible route
of the blood loss was extravascular loss (e.g., bleeding,
hematoma, catheter aspiration, etc.) rather than intravas-
cular hemolysis. Hence, the amount of the procedure-
related extravascular blood loss (EVBL) could be esti-
mated by the following equations [2]:
Blood volume = plasma volume/(1 − Hct) = BW
× (60% × 40% × 20%)/(1 − Hct);
EVBL (L) = BW (kg) × (60% × 40% × 20%)
× Hct/[(1 − baseline Hct)
(1 − baseline Hct + Hct)]
In a male patient with a BW of 70 kg, baseline Hct
40%, Hct 6%, his estimated EVBL would be 510 mL.
Actually, the average amount of EVBL after PCI rarely
exceeded 100∼200 mL. This could not explain the large
gap from the estimated data. On the contrary, Hct might
also be attributed to fluid retention-induced hemodi-
lution secondary to CIN. The proportional increase of
serum creatinine must overcome the dilute effect of
acute fluid retention before meeting the definition of
CIN (i.e., an increase of ≥25% or ≥0.5 mg/dL in pre-
PCI serum creatinine at 48 hours post-PCI) [3, 4]. Precise
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examinations of postprocedural change of BW with cor-
relation to Hct may help to clarify this issue.
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Reply from the Authors
We read with interest the letter from Lai et al [1], and
we thank them for their interest in our study [2]. The
authors raise the question that the association between
contrast-induced nephropathy (CIN) and drop in hema-
tocrit after percutaneous coronary intervention found
in our study might be explained by a greater extent of
hemodilution and, consequently, lower hematocrit in pa-
tients with CIN. While accepting this point of view as a
plausible explanation of our finding, we consider that this
does not deny the role of procedure-related blood loss in
the genesis of CIN. Lai et al reasonably state that, based
on the described calculations, the blood loss should be as
much as 510 mL to cause the observed change in hema-
tocrit level. Though the accurate amount of blood loss
cannot be assessed retrospectively, a higher drop in hema-
tocrit in our study was associated with significantly higher
rates of hemorrhagic complications and blood product
transfusion (data not published), supporting the role of
blood loss in the genesis of CIN (see Table 1).
As we mention in the Discussion section of the
manuscript, a more significant drop in hematocrit may
also be attributed to the higher incidence of periproce-
dural hypotension (due to bleeding and/or hemodynamic
instability), and to subsequent hemodilution following
more intensive fluid replacement therapy. We certainly
support the idea of periprocedural monitoring of body
weight in patients undergoing contrast medium exposure;
this should be part of the comprehensive approach to elu-
cidate the relation between drop in hematocrit and CIN,
Table 1. Incidence of access site hematoma and blood transfusion in
relation to drop in hematocrit
Quintiles of drop in hematocrit %
>2.2 to >3.9 to >5.4 to P
≤2.2 ≤3.9 ≤5.4 ≤7.4 >7.4 value
Hematoma % 4.1 4.6 5.4 7.3 23.0 ≤0.0001
Transfusion % 1.3 1.3 2.4 2.5 17.7 ≤0.0001
along with data on periprocedural hemodynamics, hydra-
tion volume, and urine output.
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PAI-1 in diabetic nephropathy
To the Editor: The mechanisms by which plasminogen
activator inhibitor-1 (PAI-1), the main plasminogen acti-
vator inhibitor, promotes fibrosis in a number of exper-
imental models, are still intensely debated. On the one
hand, PAI-1 is supposed to inhibit extracellular matrix
degradation by preventing plasmin formation. On the
other hand, it has been shown to prevent transforming
growth factor (TGF) beta activation and, thus, to pre-
vent extracellular matrix production [1]. Nicholas et al
recently provided experimental, in vivo data suggesting
that PAI-1 deficiency might be helpful in the prevention
of diabetic nephropathy: when compared to wild-type an-
imals, PAI-1 knockout mice have, thus, a lower urinary
albumin excretion and a lower synthesis of fibronectin
in the kidney after streptozotocin injection [2]. Interest-
ingly, PAI-1 is reported by these authors to enhance TGF
beta synthesis by mesangial cells, a finding that is some-
what provocative because TGF beta is itself a potent en-
hancer of the PAI-1 promoter gene, and because recent
works by Luttun et al and our group demonstrated that
PAI-1 plays a critical role in the regulation of the TGF
beta activation (i.e., PAI-1 inhibits TGF-beta activation)
[3, 4]. Moreover, in Nicholas’ study, the induction of TGF-
beta synthesis, at the mRNA and at the protein level, in
